Subsequent Events	3 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Acquisition of LaCorium Health On July 1, 2026, we completed the previously announced acquisition of LaCorium Health for approximately $150.0 million in cash. LaCorium Health is a leader in Australian therapeutic skin care products sold under the Dermal Therapy, Flexitol, and Crampeze brands. In conjunction with this acquisition, we borrowed an additional $95.0 million under our Term Loan Credit Agreement. We used the proceeds from this loan and cash on hand to finance this transaction. We are currently evaluating the fair values of assets acquired and liabilities assumed. Senior Notes On July 15, 2026, Prestige Brands, Inc. issued $400.0 million aggregate principal amount of 6.25% 2026 Senior Notes due in 2034 pursuant to an indenture, dated July 15, 2026 (the “Indenture”), among Prestige Brands, the guarantors party thereto (including the Company) and U.S. Bank Trust Company, National Association, as trustee. The Indenture provides, among other things, that interest will be payable on the 2026 Senior Notes on January 15 and July 15 of each year, beginning on January 15, 2027, until their maturity date of July 15, 2034. We used the net proceeds from the 2026 Senior Notes, together with cash on hand, to redeem all $400.0 million of our outstanding 5.125% 2019 Senior Notes, and to pay related expenses. Director Equity Grants Pursuant to the 2020 Plan, each of the independent members of the Board of Directors received a grant of 2,981 RSUs on August 4, 2026. The RSUs fully vest one year after receipt of the award, subject to the continued service of the director on such vesting date, and will be settled by delivery to each director of one share of our common stock for each vested RSU either (a) at the election of the director prior to the grant date, immediately upon vesting, or (b) promptly following the earliest of (i) such director's death, (ii) such director's separation from service or (iii) a change in control of the Company.

On July 1, 2026, we completed the previously announced acquisition of LaCorium Health for approximately $150.0 million in cash. LaCorium Health is a leader in Australian therapeutic skin care products sold under the Dermal Therapy, Flexitol, and Crampeze brands. In conjunction with this acquisition, we borrowed an additional $95.0 million under our Term Loan Credit Agreement. We used the proceeds from this loan and cash on hand to finance this transaction. We are currently evaluating the fair values of assets acquired and liabilities assumed.

On July 15, 2026, Prestige Brands, Inc. issued $400.0 million aggregate principal amount of 6.25% 2026 Senior Notes due in 2034 pursuant to an indenture, dated July 15, 2026 (the “Indenture”), among Prestige Brands, the guarantors party thereto (including the Company) and U.S. Bank Trust Company, National Association, as trustee. The Indenture provides, among other things, that interest will be payable on the 2026 Senior Notes on January 15 and July 15 of each year, beginning on January 15, 2027, until their maturity date of July 15, 2034. We used the net proceeds from the 2026 Senior Notes, together with cash on hand, to redeem all $400.0 million of our outstanding 5.125% 2019 Senior Notes, and to pay related expenses.

Pursuant to the 2020 Plan, each of the independent members of the Board of Directors received a grant of 2,981 RSUs on August 4, 2026. The RSUs fully vest one year after receipt of the award, subject to the continued service of the director on such vesting date, and will be settled by delivery to each director of one share of our common stock for each vested RSU either (a) at the election of the director prior to the grant date, immediately upon vesting, or (b) promptly following the earliest of (i) such director's death, (ii) such director's separation from service or (iii) a change in control of the Company.